BT032: A Novel NLRP1 & NLRP3 Inhibitor to Treat Pulmonary Inflammation
Time: 11:30 am
day: Day 1 - Track B - Morning
Details:
- BT032 is a novel first in class NLRP1 and NLRP3 inhibitor
- BT032 directly targets NLRP1 and NLRP3 activity
- BT032 reduces IAV-induced pulmonary inflammation in vivo
